EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders

Md Rajdoula Rafe, Pranoy Saha, Stephen Temitayo Bello

Behavioural Brain Research · 2024-08 · 472 · 115173

DOI: 10.1016/j.bbr.2024.115173 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Behavioural Brain Research, 2024-08. Verfasst von Md Rajdoula Rafe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China; Department of Pharmacy, Jagannath University, Dhaka 1100, Ba…. Hauptthemen laut MEDLINE: Receptors, N-Methyl-D-Aspartate. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 127 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glutamate activates the NMDARs, significantly affecting multiple processes such as learning, memory, synaptic integration, and excitatory transmission in the central nervous system. Uncontrolled activation of NMDARs is a significant contributor to synaptic dysfunction. Having a properly functioning NMDAR and synapse is crucial for maintaining neuronal communication. In addition, the dysfunction of NMDAR and synapse function could contribute to the development of neurological disorders at the neuronal level; hence, targeting NMDARs with antagonists in the fight against neurological disorders is a promising route. Recently published results from the animal study on different kinds of brain diseases like stroke, epilepsy, tinnitus, ataxia, Alzheimer's disease, Parkinson's disease, and spinal cord injury have demonstrated promising therapeutic scopes. Several NMDA receptor antagonists, such as memantine, MK801, ketamine, ifenprodil, gacyclidine, amantadine, agmatine, etc., showed encouraging results against different brain disease mouse models. Given the unique expression of different subunits of the well-organized NMDA receptor system by neurons. It could potentially lead to the development of medications specifically targeting certain receptor subtypes. For a future researcher, conducting more targeted research and trials is crucial to fully understand and develop highly specific medications with good clinical effects and potential neuroprotective properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, N-Methyl-D-AspartateAnimalsHumansExcitatory Amino Acid AntagonistsNervous System DiseasesNeuroprotective Agents

Stichwörter der Autor:innen

AntagonistsDiseaseN-methyl-D-aspartate (NMDA)NeurologicalReceptors

Substanzen

Receptors, N-Methyl-D-AspartateExcitatory Amino Acid AntagonistsNeuroprotective Agents

Autor:innen und Institutionen

  • Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China; Department of Pharmacy, Jagannath University, Dhaka 1100, Bangladesh.
  • Department of Pharmacy, Jagannath University, Dhaka 1100, Bangladesh.
  • Department of Neuroscience, City University of Hong Kong, Kowloon, Hong Kong SAR, China; Centre for Regenerative Medicine and Health, Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences, New Territo…

Zitieren

APA

Rafe, M. R., Saha, P., & Bello, S. T. (2024). Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders. Behavioural Brain Research, 472, 115173. https://doi.org/10.1016/j.bbr.2024.115173

Vancouver

Rafe MR, Saha P, Bello ST. Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders. Behavioural Brain Research. 2024;472:115173. doi:10.1016/j.bbr.2024.115173

BibTeX
@article{Rafe2024,
  author = {Rafe, Md Rajdoula and Saha, Pranoy and Bello, Stephen Temitayo},
  title = {Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders},
  journal = {Behavioural Brain Research},
  year = {2024},
  volume = {472},
  pages = {115173},
  doi = {10.1016/j.bbr.2024.115173}
}
Kostenlos starten →